| TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081, 2019 | 310 | 2019 |
| Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor 2–positive early breast cancer and tumors≤ 2 cm: a meta-analysis of the randomized … CC O'Sullivan, I Bradbury, C Campbell, M Spielmann, EA Perez, ... Journal of Clinical Oncology 33 (24), 2600, 2015 | 131 | 2015 |
| Beyond breast and ovarian cancers: PARP inhibitors for BRCA mutation-associated and BRCA-like solid tumors CC O’Sullivan, DH Moon, EC Kohn, JM Lee Frontiers in oncology 4, 42, 2014 | 116 | 2014 |
| The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer C O'Sullivan, M Edgerly, M Velarde, J Wilkerson, AM Venkatesan, ... The Journal of Clinical Endocrinology & Metabolism 99 (4), 1291-1297, 2014 | 111 | 2014 |
| Evolving standards of care and new challenges in the management of HER2‐positive breast cancer GM Choong, GD Cullen, CC O’Sullivan CA: a cancer journal for clinicians 70 (5), 355-374, 2020 | 101 | 2020 |
| Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum‐resistant or‐refractory epithelial ovarian cancer AM Noonan, KP Bunch, JQ Chen, MA Herrmann, JM Lee, EC Kohn, ... Cancer 122 (4), 588-597, 2016 | 90 | 2016 |
| Updates in the evaluation and management of breast cancer CC O'Sullivan, CL Loprinzi, TC Haddad Mayo Clinic Proceedings 93 (6), 794-807, 2018 | 60 | 2018 |
| Current challenges in the management of breast cancer brain metastases CC O’Sullivan, NN Davarpanah, J Abraham, SE Bates Seminars in oncology 44 (2), 85-100, 2017 | 53 | 2017 |
| Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors CC O’Sullivan International journal of cancer and clinical research 2 (4), 2015 | 41 | 2015 |
| Regional lymphadenopathy following COVID-19 vaccination: literature review and considerations for patient management in breast cancer care E Garreffa, A Hamad, CC O'Sullivan, AZ Hazim, J York, S Puri, A Turnbull, ... European Journal of Cancer 159, 38-51, 2021 | 40 | 2021 |
| ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment CC O’Sullivan, M Lindenberg, C Bryla, N Patronas, CJ Peer, ... Breast cancer research and treatment 160, 51-59, 2016 | 36 | 2016 |
| The emerging role of CDK4/6i in HER2-positive breast cancer CC O’Sullivan, VJ Suman, MP Goetz Therapeutic Advances in Medical Oncology 11, 1758835919887665, 2019 | 32 | 2019 |
| Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer S Nowsheen, PV Viscuse, CC O’Sullivan, NP Sandhu, TC Haddad, ... Current breast cancer reports 9, 173-182, 2017 | 32 | 2017 |
| Targeting prolactin receptor (PRLR) signaling in PRLR-positive breast and prostate cancer CC O’Sullivan, SE Bates The oncologist 21 (5), 523-526, 2016 | 31 | 2016 |
| Therapeutic considerations when treating HER2-positive metastatic breast cancer CC O’Sullivan, KL Smith Current breast cancer reports 6, 169-182, 2014 | 29 | 2014 |
| Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period CC O’Sullivan, S Irshad, Z Wang, Z Tang, C Umbricht, GL Rosner, ... Breast cancer research and treatment 180, 695-706, 2020 | 27 | 2020 |
| Pertuzumab: evolving therapeutic strategies in the management of HER2-overexpressing breast cancer CC O'Sullivan, SM Swain Expert opinion on biological therapy 13 (5), 779-790, 2013 | 27 | 2013 |
| Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer CC O'Sullivan, RM Connolly Oncology 28 (3), 186-186, 2014 | 26 | 2014 |
| The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl JL Dine, CC O’Sullivan, D Voeller, YE Greer, KJ Chavez, CM Conway, ... Breast cancer research and treatment 155, 235-251, 2016 | 24 | 2016 |
| Translational Breast Cancer Research Consortium TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive … RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... J Clin Oncol 37 (13), 1081-1089, 2019 | 20 | 2019 |
